Clinical Trial Update: Ngenla Subcutaneous Injection Special Investigation

View source ↗

Summary

Pfizer reports an ongoing clinical trial evaluating Ngenla (somatrogon) for growth hormone deficiency without epiphyseal closure. The study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• NGENLA (SOMATROGON-GHLA)

Snippet

Sponsor: Pfizer | Conditions: Growth Hormone Deficiency Without Epiphyseal Closure | Status: ACTIVE_NOT_RECRUITING